Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 belzutifan monotherapy study in advanced PPGL, pancreatic neuroendocrine tumors, and VHL-associated tumors
MOH_2022-12-05_012018Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of belzutifan in pheochromocytoma, Paraganglioma (PGL), islet cell tumor and 1 more (3 cohorts), sponsored by Merck & Co. Primary endpoints: Safety and Antitumor activity. Started Jul 2022; status: recruiting.
02
Drugs
belzutifan
03
Conditions
pheochromocytomaParaganglioma (PGL)islet cell tumorvon Hippel–Lindau disease (VHL)
Beyond the preview
Go deeper on MOH_2022-12-05_012018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-12-05_012018.